Holen Sie sich die Stockscreener-App
11.57
4.80%
0.53
Schlusskurs vom Vortag:
$11.04
Offen:
$11
24-Stunden-Volumen:
1.97M
Relative Volume:
1.24
Marktkapitalisierung:
$1.96B
Einnahmen:
$68.56M
Nettoeinkommen (Verlust:
$-437.99M
KGV:
-3.6569
EPS:
-3.1639
Netto-Cashflow:
$-396.61M
1W Leistung:
+9.46%
1M Leistung:
+10.09%
6M Leistung:
+12.55%
1J Leistung:
+79.94%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$10.03
$11.63
52-Wochen-Spanne:
$4.815
$12.00
Vir Biotechnology Inc Stock (VIR) Company Profile
Firmenname
Vir Biotechnology Inc
Sektor
Branche
Telefon
415-906-4324
Adresse
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR vs VRTX, REGN, MRNA, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
11.57 | 1.96B | 68.56M | -437.99M | -396.61M | -3.1639 |
VRTX
Vertex Pharmaceuticals Inc
|
521.03 | 132.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
816.10 | 84.02B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
207.97 | 83.03B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
882.48 | 55.50B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
366.06 | 41.41B | 5.76B | 514.49M | 1.10B | 4.4813 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-09-03 | Eingeleitet | Evercore ISI | Outperform |
| 2025-08-27 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-01-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-09-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-03-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-02-21 | Hochstufung | Goldman | Neutral → Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | Eingeleitet | SVB Leerink | Outperform |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-03-03 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-09-22 | Herabstufung | Goldman | Buy → Neutral |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-01-27 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-01-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-05 | Eingeleitet | BofA Securities | Buy |
| 2020-09-14 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-11 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-08-20 | Eingeleitet | Needham | Buy |
| 2020-03-19 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-03-13 | Herabstufung | Goldman | Buy → Neutral |
| 2020-02-27 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-11-14 | Eingeleitet | Robert W. Baird | Neutral |
| 2019-11-05 | Eingeleitet | Barclays | Overweight |
| 2019-11-05 | Eingeleitet | Cowen | Outperform |
| 2019-11-05 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Vir Biotechnology Inc Aktie (VIR) Neueste Nachrichten
Vir Biotechnology (NASDAQ:VIR) Breaks Higher: Real Momentum? - Kalkine Media
Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth? - Zacks Investment Research
Vir Biotechnology Sells 1.76 Million Shares to Gilead in $25M Stock Deal - Kalkine Media
VIR 8-K & SEC Filings - Yahoo! Finance Canada
Vir Biotechnology (VIR) Slides 4.25% to $10.82 as Support at $10.28 Comes Into FocusBPI Bear Confirmed - dars.gov.et
Vir Biotechnology (VIR) Slides 4.25% to $10.82 as Support at $10.28 Comes Into FocusSpring Pattern - dars.gov.et
Vir Biotechnology (VIR) Slides 4.25% to $10.82 as Support at $10.28 Comes Into FocusETF AUM Growth - https://www.siam.in/
Can Vir Biotechnology (NASDAQ:VIR) Keep Climbing After Latest Target Boost? - Kalkine Media
Aziz Sawaf, CFO of Vir Biotechnology (VIR), reports zero directly held common shares. - Stock Titan
One talk will cover hepatitis D response data through 96 weeks; another will study liver immune cells. - Stock Titan
A $150K sign-on bonus, contingent on continued employment, awaits Vir Biotechnology (VIR)'s incoming CFO. - Stock Titan
Vir Biotechnology, Inc. (NASDAQ:VIR) Stock Rated "Moderate Buy" by Sell-Side Brokerages - MarketBeat
Vir Biotechnology (NASDAQ:VIR) Nears Key Hepatitis Delta Readout - kalkinemedia.com
Vir Biotechnology (NasdaqGS:VIR) Stock Forecast & Analyst Predictions - Simply Wall Street
Vir Biotechnology Stock Price Forecast. Should You Buy VIR? - StockInvest.us
Engineers Gate Manager LP Sells 121,964 Shares of Vir Biotechnology, Inc. $VIR - MarketBeat
Former Vir (NASDAQ: VIR) officer sold $315K in stock, with more share sales planned - Stock Titan
WINTON GROUP Ltd Trims Stake in Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology (VIR) ex-officer to sell 28,333 shares from option exercise - Stock Titan
How (VIR) Movements Inform Risk Allocation Models - Stock Traders Daily
Legal & General Group Plc Invests $2.76 Million in Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Bank of New York Mellon Corp Makes New $7.08 Million Investment in Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology stock gains on conference catalyst - ad-hoc-news.de
Man Group plc Takes $1.54 Million Position in Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology stock gains on new 52-week high and conference appearance - ad-hoc-news.de
Corient Private Wealth LP Invests $3.17 Million in Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology (NASDAQ:VIR) Sets New 52-Week HighShould You Buy? - MarketBeat
Vir Biotechnology stock gains on conference participation and 52-week high - ad-hoc-news.de
Vir Biotechnology stock hits 52-week high at 11.66 USD By Investing.com - Investing.com South Africa
Vir Biotechnology stock hits 52-week high at 11.66 USD By Investing.com - Investing.com Canada
Vir Biotechnology stock hits 52-week high at 11.66 USD By Investing.com - Investing.com India
Vir Biotechnology stock hits 52-week high at 11.66 USD By Investing.com - Investing.com Nigeria
Vir Biotechnology stock hits 52-week high at 11.66 USD - investing.com
Vir Biotechnology stock hits 52-week high at 11.66 USD By Investing.com - Investing.com UK
Vir Biotechnology (NASDAQ:VIR) Trading 4.8% HigherHere's What Happened - MarketBeat
Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - Business Wire
Vir Biotechnology CEO to speak at Morgan Stanley conference Sept. 14 - Stock Titan
Deutsche Bank AG Acquires Shares of 134,258 Vir Biotechnology, Inc. $VIR - MarketBeat
ARCH Venture Management LLC Invests $129.35 Million in Vir Biotechnology, Inc. $VIR - MarketBeat
Algert Global LLC Purchases 315,969 Shares of Vir Biotechnology, Inc. $VIR - MarketBeat
ADAR1 Capital Management LLC Acquires New Shares in Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology (NASDAQ: VIR) ex-officer lines up more sales - Stock Titan
Vir Biotechnology (NASDAQ:VIR) Shares Up 8.1%Time to Buy? - MarketBeat
Vir Biotechnology (NASDAQ: VIR) officer plans 14,352-share sale after 25K sale - Stock Titan
Vir Biotechnology (NASDAQ: VIR) ex-officer files notice for potential $245K stock sale - Stock Titan
Vir Biotechnology on Track for Record Winning Streak -- Data Talk - Bitget
Vir (VIR) Close and Levels: Adds 1.06% to Close at $9.49 in the Latest Reading; Key Levels: the $9.02 to $9.96 Range Remains in Focus in Latest TradingRevenue Weighted - vinanet.vn
The Bull Case For Vir Biotechnology (VIR) Could Change Following A Sudden Swing To Quarterly Profitability - Sahm
Vir Biotechnology’s Earnings Call Signals Data-Driven Momentum - TipRanks
Finanzdaten der Vir Biotechnology Inc-Aktie (VIR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Vir Biotechnology Inc-Aktie (VIR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| O'Byrne Jason | Former Officer |
Sep 09 '26 |
Proposed Sale |
11.13 |
28,333 |
315,241 |
0 |
| O'Byrne Jason | Former Officer |
Aug 25 '26 |
Proposed Sale |
10.48 |
23,148 |
242,591 |
0 |
| O'Byrne Jason | Former Officer |
Aug 24 '26 |
Proposed Sale |
9.90 |
14,352 |
142,124 |
0 |
| O'Byrne Jason | Former Officer |
Aug 21 '26 |
Proposed Sale |
9.81 |
25,000 |
245,297 |
0 |
| Ramasastry Saira | Former Director |
Jun 29 '26 |
Proposed Sale |
10.32 |
16,000 |
165,139 |
0 |
| Napolitano Janet | Director |
Jun 01 '26 |
Sale |
9.45 |
3,200 |
30,240 |
21,216 |
| Sabatini Brent | SVP, Chief Accounting Officer |
Jun 01 '26 |
Sale |
9.45 |
379 |
3,582 |
61,902 |
| Sabatini Brent | Officer |
Jun 01 '26 |
Proposed Sale |
9.45 |
379 |
3,582 |
0 |
| Napolitano Janet | Director |
Jun 01 '26 |
Proposed Sale |
9.45 |
3,200 |
30,240 |
0 |
| SATO VICKI L | Director |
May 01 '26 |
Sale |
10.05 |
22,000 |
221,025 |
1,078,391 |
0.23%
1.80%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):